As recurrence in a tapering-off pattern extends up to 15 years,38 longer follow-up is desirable for more definitive statements on long-term safety of FP in this population, in particular for women with estrogen receptor–positive BC.39 Nevertheless, the specific analyses restricted to women with follow-up longer than 5 years in this study also provide reassuring findings. The gene discussed is ESR1; the disease is breast cancer.